ALERGOLOGÍA PARA MÉDICOS Y PACIENTES 2021

EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy Authors:   Pajno GB1, Fernandez-Rivas M2, Arasi S1,3, Roberts G4,5,6, Akdis CA7, Alvaro-Lozano M8, Beyer K3,9, Bindslev-Jensen C10, Burks W11, Ebisawa M12, Eigenmann P13, Knol E14, Nadeau KC15, Poulsen LK16, van Ree R17, Santos AF18,19,20, du Toit G18,19,20, Dhami S21, Nurmatov U22, Boloh Y23, Makela M24, O'Mahony L7, Papadopoulos N25, Sackesen C26, Agache I27, Angier E28, Halken S29, Jutel M30,31, Lau S3, Pfaar O32,33, Ryan D34, Sturm G35,36, Varga EM37, van Wijk RG38, Sheikh A34, Muraro A39 1 Department of Pediatrics, Allergy Unit, University of Messina, Messina, Italy. 2 Allergy Department, IdISSC, Hospital Clínico San Carlos, Madrid, Spain. 3 Pediatric Pneumology and Immunology, Charité Universitätsmedizin, Berlin, Germany. 4 The David Hide Asthma and Allergy Research Centre, St Mary's Hospital, Newport, UK. 5 NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Fou

Atopic dermatitis. Authors:  Weidinger S1, Beck LA2, Bieber T3,4, Kabashima K5, Irvine AD6,7,8. 1 Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany. sweidinger@dermatology.uni-kiel.de. 2 Department of Dermatology, Medicine and Pathology, University of Rochester Medical Center, Rochester, NY, USA. 3 Department of Dermatology and Allergy, University of Bonn, Bonn, Germany. 4 The Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland. 5 Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan. 6 Paediatric Dermatology, Our Lady's Children's Hospital Crumlin, Dublin, Ireland. irvinea@tcd.ie. 7 National Children's Research Centre, Crumlin, Dublin, Ireland. irvinea@tcd.ie. 8 Clinical Medicine, Trinity College Dublin, Dublin, Ireland. irvinea@tcd.ie. Abstract:  Atopic dermatitis (AD) is the most common chronic inflammatory skin disease, with a lifetime prevalence of up

Commonality of the IL-4/IL-13 pathway in atopic diseases. Authors: Gandhi NA1, Pirozzi G2, Graham NMH3. 1 a Clinical Sciences , Regeneron Pharmaceuticals, Inc. , Tarrytown , New York , USA. 2 b Research and Development , Sanofi, Bridgewater , New Jersey , USA. 3 c Project Direction , Regeneron Pharmaceuticals, Inc. , Tarrytown , New York , USA. Abstract:  Allergy results from an aberrant Type 2 inflammatory response, triggered by a wide range of environmental antigens (allergens) that lead to various immune responses, culminating in the production of immunoglobulin E (IgE). Two key cytokines, interleukin (IL)-4 and IL-13, are critical to the induction and perpetuation of the Type 2 response, and have been implicated in multiple atopic diseases. Area covered: This review summarizes recent milestone developments that have elucidated components of the pathogenesis of atopic diseases such as atopic dermatitis (AD), asthma, and chronic sinusitis with nasal polyposis (CSwNP). Exp

Targeting key proximal drivers of type 2 inflammation in disease. Authors:   Gandhi NA1, Bennett BL1, Graham NM1, Pirozzi G2, Stahl N1, Yancopoulos GD1. 1 Regeneron Pharmaceuticals, Tarrytown, New York 10591, USA. 2 Research and Development, Sanofi, Bridgewater, New Jersey 08807, USA. Abstract:  Systemic type 2 inflammation encompassing T helper 2 (TH2)-type responses is emerging as a unifying feature of both classically defined allergic diseases, such as asthma, and a range of other inflammatory diseases. Rather than reducing inflammation with broad-acting immunosuppressants or narrowly targeting downstream products of the TH2 pathway, such as immunoglobulin E (IgE), efforts to target the key proximal type 2 cytokines - interleukin-4 (IL-4), IL-5 and IL-13 - represent a promising strategy to achieve therapeutic benefit across multiple diseases. After several initial disappointing clinical results with therapies targeting IL-4, IL-5 or IL-13 in asthma, applying a personaliz

Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial. Authors:  Banerji A1, Riedl MA2, Bernstein JA3, Cicardi M4, Longhurst HJ5, Zuraw BL2, Busse PJ6, Anderson J7, Magerl M8, Martinez-Saguer I9, Davis-Lorton M10, Zanichelli A4, Li HH11, Craig T12, Jacobs J13, Johnston DT14, Shapiro R15, Yang WH16, Lumry WR17, Manning ME18, Schwartz LB19, Shennak M20, Soteres D21, Zaragoza-Urdaz RH22, Gierer S23, Smith AM24, Tachdjian R25, Wedner HJ26, Hebert J27, Rehman SM28, Staubach P29, Schranz J30, Baptista J30, Nothaft W30, Maurer M8; HELP Investigators. 1 Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston. 2 Division of Rheumatology, Allergy & Immunology, University of California, San Diego. 3 Department of Internal Medicine/Allergy Section Cincinnati, University of Cincinnati College of Medicine, Cincinnati, Ohio. 4 Department of

Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of "Real-world" Evidence. Authors:  Tharp MD1, Bernstein JA2, Kavati A3, Ortiz B4, MacDonald K5, Denhaerynck K5,6, Abraham I5,7,8,9, Lee CS5,10. 1 Department of Dermatology, Rush University Medical Center, Chicago, Illinois. 2 Division of Immunology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio. 3 US Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey. 4 Respiratory Medical Unit, US Clinical Development and Medical Affairs, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey. 5 Matrix45, Tucson, Arizona. 6 Department of Public Health, University of Basel, Basel, Switzerland. 7 Associate Editor for Quantitative Methods. 8 Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, T

Rhinitis in children and adolescents with asthma: Ubiquitous, difficult to control, and associated with asthma outcomes. Authors:  Togias A1, Gergen PJ1, Hu JW2, Babineau DC3, Wood RA4, Cohen RT5, Makhija MM6, Khurana Hershey GK7, Kercsmar CM7, Gruchalla RS8, Liu AH9, Wang E10, Kim H10, Lamm CI11, Bacharier LB12, Pillai D13, Sigelman SM1, Gern JE14, Busse WW14. 1 Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, Bethesda, Md. 2 Rho Federal Systems Division, Chapel Hill, MC. Electronic address: jack_hu@rhoworld.com. 3 Rho Federal Systems Division, Chapel Hill, MC. 4 Division of Allergy and Immunology, Johns Hopkins University School of Medicine, Baltimore, Md. 5 Department of Pediatrics, Boston University School of Medicine, Boston, Mass. 6 Division of Allergy and Immunology, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Ill. 7 Division of Asthma Research and Division of Pulmonary Medicine, C

Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy The PEPITES Randomized Clinical Trial Authors:  Fleischer DM1, Greenhawt M1, Sussman G2, Bégin P3, Nowak-Wegrzyn A4, Petroni D5, Beyer K6, Brown-Whitehorn T7, Hebert J8, Hourihane JO9, Campbell DE10, Leonard S11, Chinthrajah RS12, Pongracic JA13, Jones SM14, Lange L15, Chong H16, Green TD16,17, Wood R18, Cheema A19, Prescott SL20, Smith P21, Yang W22, Chan ES23, Byrne A24, Assa'ad A25, Bird JA26, Kim EH27, Schneider L28, Davis CM29, Lanser BJ30, Lambert R17, Shreffler W31. 1 Children's Hospital Colorado, University of Colorado Denver School of Medicine, Aurora. 2 Gordon Sussman Clinical Research, Toronto, Ontario, Canada. 3 Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada. 4 Icahn School of Medicine at Mount Sinai, New York, New York. 5 Northwest Allergy and Asthma Center, University of Washington Children's Ho

Rapid Onset of Effect of Benralizumab on Morning Peak Expiratory Flow in Severe, Uncontrolled Asthma. Authors: Chupp G1, Lugogo NL2, Kline JN3, Ferguson GT4, Hirsch I5, Goldman M5, Zangrilli JG5, Trudo F6. 1 Yale Center for Asthma and Airway Disease, New Haven, CT, USA. Electronic address: geoffrey.chupp@yale.edu. 2 University of Michigan Medical Center, Ann Arbor, MI, USA. 3 University of Iowa Carver College of Medicine, Iowa City, IA, USA. 4 Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USA. 5 AstraZeneca, Gaithersburg, MD, USA. 6 AstraZeneca, Wilmington, DE, USA. DOI:   10.1016/j.anai.2019.02.016

Treatment of urticarial vasculitis: A systematic review Authors:  Kolkhir P1, Grakhova M2, Bonnekoh H3, Krause K3, Maurer M4. 1 Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Dermatology and Allergy, Allergie-Centrum-Charité, Berlin, Germany; I.M. Sechenov First Moscow State Medical University, Division of Immune-mediated skin diseases, Moscow, Russia. 2 Regional Clinical Hospital No. 1, Tyumen, Russia. 3 Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Dermatology and Allergy, Allergie-Centrum-Charité, Berlin, Germany. 4 Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Dermatology and Allergy, Allergie-Centrum-Charité, Berlin, Germany. Electro

Staphylococcus aureus impairs sinonasal epithelial repair: Effects in patients with chronic rhinosinusitis with nasal polyps and control subjects. Authors: Valera FCP1, Ruffin M2, Adam D2, Maillé É3, Ibrahim B4, Berube J5, Rousseau S5, Brochiero E2, Desrosiers MY6. 1 Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada; Division of Otorhinolaryngology, Ribeirão Preto Medical School, University of São Paulo (FMRP-USP), Ribeirão Preto, Brazil. 2 Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada; Département de Médecine, Université de Montréal, Montreal, Quebec, Canada. 3 Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada. 4 Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada; Department of Otolaryngology, Centre Hospitalier de l'Université de Mont

Development of a tool for screening adverse food reactions and food allergy in Portuguese children. Authors: Jorge A1, Santos Silva M2, Lozoya-Ibánez C3, Lorente F4, Sarinho E5, Afonso RM6, Pereira H6, Taborda-Barata L7. 1 CICS - Health Sciences Research Centre, University of Beira Interior, Avenida Infante D. Henrique, 6200-506 Covilhã, Portugal; Department of Paediatrics, Cova da Beira Hospital Centre, Covilhã, Portugal. 2 Quality Management Unit, Cova da Beira Hospital Centre, Covilhã, Portugal. 3 CICS - Health Sciences Research Centre, University of Beira Interior, Avenida Infante D. Henrique, 6200-506 Covilhã, Portugal; Allergy Department, Castelo Branco Local Health Unit, Castelo Branco, Portugal. 4 Department of Pediatrics, Salamanca University Hospital, Spain. 5 Center for Research in Allergy and Clinical Immunology (HC/UFPE), Federal University of Pernambuco, Recife, Brazil. 6 Psychology and Education Department, University of Beira Interior, Covilhã, Portugal. 7

Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis. Authors:  Snast I1, Reiter O1, Hodak E1,2, Friedland R3, Mimouni D4,5, Leshem YA1,2. 1 Department of Dermatology, Beilinson Hospital, Rabin Medical Center, 4941492, Petah Tikva, Israel. 2 Sackler Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel. 3 Schneider Children's Medical Center, Petah Tikva, Israel. 4 Department of Dermatology, Beilinson Hospital, Rabin Medical Center, 4941492, Petah Tikva, Israel. daniel.mimouni@gmail.com. 5 Sackler Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel. daniel.mimouni@gmail.com Abstract: BACKGROUND: Current systemic treatments for atopic dermatitis (AD) offer limited efficacy and are often restricted by safety concerns. Biologics may address the unmet need for improved AD therapeutics. OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of biologic agents in AD. METHODS: A systemati

Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America Authors: Ivan Cherrez-Ojeda a,b,*, Marcus Maurer c, Jonathan A. Bernstein d, Emanuel Vanegas a,b, Miguel Felix a,b, German D. Ramon e, Luis Felipe Ensina f, Jose Ignacio Larco Sousa g, Edgar Emilio Matos Benavides h, R. Cardona Villa i, P. Latour Staffeld j,k, Blanca María Morfin-Maciel l, Jose Mori m, Paul Wilches C n, Valeria L. Mata a,b, Annia Cherrez b,o a Universidad Espíritu Santo, Samborondon, Ecuador b Respiralab, Respiralab Research Group, Guayaquil, Ecuador c Department of Dermatology and Allergy, Charite – Universitatsmedizin Berlin, Berlin, Germany € d University of Cincinnati College of Medicine, Department of Internal Medicine, Division of Immunology/Allergy Section, Cincinnati, OH, United States e Instituto de Alergia e Inmunología del Sur, Bahía Blanca, Prov. de Buenos Aires, Argentina f Federal University of Sao Paulo, S ~ ao Paulo, Brazil ~ g Clínica San Felipe,

Change in FEV1 and Feno Measurements as Predictors of Future Asthma Outcomes in Children. Authors: Fielding S1, Pijnenburg M2, de Jongste JC2, Pike KC3, Roberts G4, Petsky H5, Chang AB6, Fritsch M7, Frischer T7, Szefler S8, Gergen P9, Vermeulen F10, Vael R11, Turner S12. 1 Medical Statistics Team, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, Scotland. 2 Department of Paediatric Respiratory Medicine and Allergology, Erasmus MC, Sophia Children's Hospital, Rotterdam, the Netherlands. 3 Clinical and Experimental Science Academic Unit, University of Southampton, Southampton, England; Respiratory Critical Care and Anaesthesia Group, Institute of Child Health, University College London, London, England. 4 Clinical and Experimental Science Academic Unit, University of Southampton, Southampton, England. 5 Department of Respiratory and Sleep Medicine, Lady Cilento Children's Hospital, Queensland University of Technology, Brisbane, Australia. 6 Dep

Food Protein-induced Enterocolitis Syndrome: Data From a Multicenter Retrospective Study in Spain. Authors:   Díaz JJ1, Espín B2, Segarra O3, Domínguez-Ortega G4, Blasco-Alonso J5, Cano B6, Rayo A7, Moreno A8; Gastrointestinal Allergy Working Group of the Spanish Society of Pediatric Gastroenterology, Hepatology and Nutrition (SEGHNP). 1 Hospital Universitario Central de Asturias, Oviedo. 2 Hospital Infantil Virgen del Rocío, Sevilla. 3 Hospital Universitario Vall de Hebrón, Barcelona. 4 Hospital Universitario Niño Jesús, Madrid. 5 Hospital Regional Universitario de Málaga. 6 Hospital Universitario Puerta de Hierro, Madrid. 7 Hospital Severo Ochoa, Leganés. 8 Complejo Hospitalario Universitario, A Coruña, Spain. Abstract: OBJECTIVE: The aim of the study was to describe clinical, epidemiological, and management characteristics of food protein-induced enterocolitis syndrome (FPIES) cases in Spain. PATIENTS AND METHODS: Multicenter observational retrospective study.